To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.
Specifications
- Assay Type (ELISA with LOV):Competitive
- Host:
- Primary antibody reactivity:
- Description:Mycoplasma hominis IgM ELISA
- Environmentally Preferable:
- Application:Infectious Diseases
- Regulatory Status:FDA Regulated; CE Approved
- Cat. No.:75871-080
- Supplier no.:EIA-4560
- No. of tests:96 wells
Specifications
About this item
An enzyme immunoassay for the qualitative and semiquantitative determination of IgM-class antibodies to Mycoplasma hominis in serum and plasma.
- High quality assays with reproducible and reliable results
- Ready-to-use reagents with internal controls
- Very good precision and sensitivity
- Short assay time and incubation steps at room temperature
- Simple and technician friendly tests
Mycoplasma hominis is a strain of bacteriapresent in thevagina. It is one of the many organisms that may cause pelvic inflammatory disease (PID) in women. PID comprises a spectrum of inflammatory disorders of the upper genital tract among women and may include any combination of endometritis, salpingitis, tubo-ovarian abscess, and/or pelvic peritonitis. The DRG Mycoplasma hominis IgM ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA). Patient samples are diluted with Sample Diluentand additionally incubated withIgG-RF-Sorbent, containing hyper-immune anti-human IgG-class antibody to eliminate competitive inhibition from specific IgG and to remove rheumatoid factors. This pretreatment avoids false negative or false positive results. Microtiter wells as a solid phase are coated with Mycoplasma hominis surface antigen p120. Diluted patient specimens and ready-for-use controls are pipetted into these wells. During incubation Mycoplasma hominis-specific antibodies of positive specimens and controls are bound to the immobilized antigens. After a washing step to remove unbound sample and control material horseradish peroxidase conjugated anti-human IgM antibodies are dispensed into the wells. During a second incubation this anti‑IgM conjugate binds specifically to IgM antibodies resulting in the formation of enzyme-linked immune complexes. After a second washing step to remove unbound conjugate the immune complexes formed (in case of positive results) are detected by incubation with TMB substrate and development of a blue color. The blue color turns into yellow by stopping the enzymatic indicator reaction with sulfuric acid. The intensity of this color is directly proportional to the amount of Mycoplasma hominis-specific IgM antibody in the patient specimen. Absorbance at 450 nm is read using an ELISA microtiter plate reader.